205 related articles for article (PubMed ID: 22205686)
21. Activating stress-activated protein kinase-mediated cell death and inhibiting epidermal growth factor receptor signaling: a promising therapeutic strategy for prostate cancer.
Kumar R; Srinivasan S; Pahari P; Rohr J; Damodaran C
Mol Cancer Ther; 2010 Sep; 9(9):2488-96. PubMed ID: 20736346
[TBL] [Abstract][Full Text] [Related]
22. Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib.
Servidei T; Riccardi A; Mozzetti S; Ferlini C; Riccardi R
Int J Cancer; 2008 Dec; 123(12):2939-49. PubMed ID: 18803287
[TBL] [Abstract][Full Text] [Related]
23. SKLB188 inhibits the growth of head and neck squamous cell carcinoma by suppressing EGFR signalling.
Barzegar M; Ma S; Zhang C; Chen X; Gu Y; Shang C; Jiang X; Yang J; Nathan CA; Yang S; Huang S
Br J Cancer; 2017 Oct; 117(8):1154-1163. PubMed ID: 28873083
[TBL] [Abstract][Full Text] [Related]
24. [The effects of genistein on epidermal growth factor receptor mediated signal transduction pathway in human ovarian carcinoma cells lines SKOV3 and its xenograft in nude mice].
Li Y; Mi C; Wu YZ; Yang SF; Yang ZQ
Zhonghua Bing Li Xue Za Zhi; 2004 Dec; 33(6):546-9. PubMed ID: 15634453
[TBL] [Abstract][Full Text] [Related]
25. Radiosensitization of epidermal growth factor receptor/HER2-positive pancreatic cancer is mediated by inhibition of Akt independent of ras mutational status.
Kimple RJ; Vaseva AV; Cox AD; Baerman KM; Calvo BF; Tepper JE; Shields JM; Sartor CI
Clin Cancer Res; 2010 Feb; 16(3):912-23. PubMed ID: 20103665
[TBL] [Abstract][Full Text] [Related]
26. Priming with EGFR tyrosine kinase inhibitor and EGF sensitizes ovarian cancer cells to respond to chemotherapeutical drugs.
Cao C; Lu S; Sowa A; Kivlin R; Amaral A; Chu W; Yang H; Di W; Wan Y
Cancer Lett; 2008 Aug; 266(2):249-62. PubMed ID: 18400375
[TBL] [Abstract][Full Text] [Related]
27. Gonadotropins upregulate the epidermal growth factor receptor through activation of mitogen-activated protein kinases and phosphatidyl-inositol-3-kinase in human ovarian surface epithelial cells.
Choi JH; Choi KC; Auersperg N; Leung PC
Endocr Relat Cancer; 2005 Jun; 12(2):407-21. PubMed ID: 15947112
[TBL] [Abstract][Full Text] [Related]
28. The chemokine CXCL1 induces proliferation in epithelial ovarian cancer cells by transactivation of the epidermal growth factor receptor.
Bolitho C; Hahn MA; Baxter RC; Marsh DJ
Endocr Relat Cancer; 2010 Dec; 17(4):929-40. PubMed ID: 20702723
[TBL] [Abstract][Full Text] [Related]
29. Ascitic fluid from advanced ovarian cancer patients compromises the activity of receptor tyrosine kinase inhibitors in 3D cell clusters of ovarian cancer cells.
Hassan W; Chitcholtan K; Sykes P; Garrill A
Cancer Lett; 2018 Apr; 420():168-181. PubMed ID: 29432847
[TBL] [Abstract][Full Text] [Related]
30. Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells.
Yue P; Zhang X; Paladino D; Sengupta B; Ahmad S; Holloway RW; Ingersoll SB; Turkson J
Oncogene; 2012 May; 31(18):2309-22. PubMed ID: 21909139
[TBL] [Abstract][Full Text] [Related]
31. Berberine induces senescence of human glioblastoma cells by downregulating the EGFR-MEK-ERK signaling pathway.
Liu Q; Xu X; Zhao M; Wei Z; Li X; Zhang X; Liu Z; Gong Y; Shao C
Mol Cancer Ther; 2015 Feb; 14(2):355-63. PubMed ID: 25504754
[TBL] [Abstract][Full Text] [Related]
32. Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2.
Chen Y; Wu J; Yan H; Cheng Y; Wang Y; Yang Y; Deng M; Che X; Hou K; Qu X; Zou D; Liu Y; Zhang Y; Hu X
Pharmacol Res; 2020 Sep; 159():105007. PubMed ID: 32561477
[TBL] [Abstract][Full Text] [Related]
33. Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.
Sato H; Yamamoto H; Sakaguchi M; Shien K; Tomida S; Shien T; Ikeda H; Hatono M; Torigoe H; Namba K; Yoshioka T; Kurihara E; Ogoshi Y; Takahashi Y; Soh J; Toyooka S
Cancer Sci; 2018 Oct; 109(10):3183-3196. PubMed ID: 30098066
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation on tumor-associated endothelial cells leads to treatment of orthotopic human colon cancer in nude mice.
Sasaki T; Kitadai Y; Nakamura T; Kim JS; Tsan RZ; Kuwai T; Langley RR; Fan D; Kim SJ; Fidler IJ
Neoplasia; 2007 Dec; 9(12):1066-77. PubMed ID: 18084614
[TBL] [Abstract][Full Text] [Related]
35. IL6-induced metastasis modulators p-STAT3, MMP-2 and MMP-9 are targets of 3,3'-diindolylmethane in ovarian cancer cells.
Zou M; Zhang X; Xu C
Cell Oncol (Dordr); 2016 Feb; 39(1):47-57. PubMed ID: 26510945
[TBL] [Abstract][Full Text] [Related]
36. Synergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways in human ovarian cancer.
Wen W; Wu J; Liu L; Tian Y; Buettner R; Hsieh MY; Horne D; Dellinger TH; Han ES; Jove R; Yim JH
Mol Cancer; 2015 May; 14():100. PubMed ID: 25928246
[TBL] [Abstract][Full Text] [Related]
37. Combination of sublethal concentrations of epidermal growth factor receptor inhibitor and microtubule stabilizer induces apoptosis of glioblastoma cells.
Failly M; Korur S; Egler V; Boulay JL; Lino MM; Imber R; Merlo A
Mol Cancer Ther; 2007 Feb; 6(2):773-81. PubMed ID: 17308073
[TBL] [Abstract][Full Text] [Related]
38. Inactivation of NF-kappaB by 3,3'-diindolylmethane contributes to increased apoptosis induced by chemotherapeutic agent in breast cancer cells.
Rahman KM; Ali S; Aboukameel A; Sarkar SH; Wang Z; Philip PA; Sakr WA; Raz A
Mol Cancer Ther; 2007 Oct; 6(10):2757-65. PubMed ID: 17913854
[TBL] [Abstract][Full Text] [Related]
39. Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines.
Pino MS; Shrader M; Baker CH; Cognetti F; Xiong HQ; Abbruzzese JL; McConkey DJ
Cancer Res; 2006 Apr; 66(7):3802-12. PubMed ID: 16585207
[TBL] [Abstract][Full Text] [Related]
40. AST1306, a novel irreversible inhibitor of the epidermal growth factor receptor 1 and 2, exhibits antitumor activity both in vitro and in vivo.
Xie H; Lin L; Tong L; Jiang Y; Zheng M; Chen Z; Jiang X; Zhang X; Ren X; Qu W; Yang Y; Wan H; Chen Y; Zuo J; Jiang H; Geng M; Ding J
PLoS One; 2011; 6(7):e21487. PubMed ID: 21789172
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
